Pulmonary Fibrosis News Moderator

A cell therapy approach based on transplanting a type of lung cells called type II alveolar cells halted scarring in a rat model of IPF. Click here to learn more.

What do you think of these findings?

People with idiopathic pulmonary fibrosis who receive a single lung transplant have a higher risk of developing lung cancer, a study found. Click here to learn more.

What do you think of these findings?

IPF patients taking antifibrotic therapies Ofev or Esbriet had a 37% lower mortality risk than those not treated, a registry-based study says. Read more here.

What do you think of these findings?

Long-term survival appears to be similar between bilateral and single lung transplants in IPF patients, a review study shows. Click here to read more.

What do you think of these findings?

Orphan drug status gives incentives to companies to support development of treatments, like AMP945 by Amplia Therapeutics, for rare diseases. Click here to learn more.

What are your thoughts on orphan drugs?

A case report supports using Ofev as monotherapy for IPF patients with advanced non‐small cell lung cancer who cannot tolerate chemotherapy.  Click here to read more about it.

What do you think of these findings?

A real-world, multi-center study in Poland confirms the effectiveness of two-year treatment with Esbriet (pirfenidone) for IPF patients. Read more about it here.

What do you think of this news?

The FDA and Health Canada extended use of Ofev, as twice daily capsule, for interstitial lung diseases with chronic worsening of fibrosis. Read more about it here.

What do you think of these findings?

Poorer survival was seen in chronic idiopathic interstitial pneumonia patients hospitalized repeatedly for acute flares and infections. Click here to learn more.

What do you think of these findings?

Lung CT scans might help predict the mortality risk in IPF patients better than the decline in forced vital capacity, a study shows. Read more here.

What do you think of these findings?

The NIH-led research network hopes for 5,000 responses to its online survey of how people with rare diseases in the US are being affected by the pandemic. Click here to learn more.

How has the global pandemic affected you so far?

Click here to read NORD’s call to action for rare disease patients on financial and legislative issues in the wake of the COVID-19 pandemic.

Which of these issues is most important to you and why?

Avalyn raised $35.5 million to support clinical studies of APO1, aerosolized pirfenidone, to treat IPF and chronic lung allograft dysfunction. Click here to read more.

What do you think of this news?

A study has linked mechanical ventilation to higher mortality rates in IPF patients previously treated with high-flow nasal cannula oxygen therapy. Read more about these findings here.

What do you think of this news?

Chronic lung infections are particularly risky for IPF patients with low oxygen pressure in the blood or high levels of the biomarker KL-6. Read more about this topic here.

What do you think of this news?

GED-0507 was seen in mice with induced pulmonary fibrosis to have benefits equal to, or greater than, two approved anti-fibrotic therapies. Read more about these findings here.

What do you think of this news?

A survey of 509 doctors in 66 countries found variations in approach given acute IPF exacerbations, reflecting a lack of clear guidelines. Read the full story here.

What do you think of this news?

According to a study, people with IPF live a much shorter time after an acute exacerbation than those with other interstitial lung diseases (ILD). Read more about these findings here.

What do you think of this news?

Surgeons in Japan were able to transplant a donated left lung into the right-side lung cavity of an IPF patient, a case study reports. Read the full story here.

What do you think of this news?

You can enter into a raffle for a chance to have your song performed on stage at NORD’s patient and family forum welcome reception. Click here find out more.

Will you be entering this contest?